Trillium Therapeutics’ (TR) “Market Perform” Rating Reaffirmed at Leerink Swann

Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL)‘s stock had its “market perform” rating restated by investment analysts at Leerink Swann in a research report issued on Friday.

Shares of TR opened at C$30.20 on Friday. Trillium Therapeutics has a 52-week low of C$28.50 and a 52-week high of C$39.45.

How to Become a New Pot Stock Millionaire

Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL) last issued its earnings results on Friday, March 9th. The company reported C($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C($1.06) by C$0.15.

TRADEMARK VIOLATION WARNING: “Trillium Therapeutics’ (TR) “Market Perform” Rating Reaffirmed at Leerink Swann” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/17/trillium-therapeutics-tr-market-perform-rating-reaffirmed-at-leerink-swann.html.

About Trillium Therapeutics

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1).

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply